Cost analysis of lung cancer management in South Western Sydney.

摘要: Introduction: Lung cancer is the leading cause of mortality in Western nations, and associated health-care costs are escalating. The aim this study was to describe current pattern resource use direct medical managing lung South Sydney, Australia. Methods: All new cases primary carcinoma discussed at Liverpool Macarthur Cancer Therapy Centre (CTC) Multidisciplinary Team meeting or seen CTC between 1 December 2005 21 2006 were reviewed. Staging investigations, hospitalisation, treatment follow-up investigations documented from first consultation last (31 October 2008 death). Cost estimates based on Australian Medicare Benefits Schedule reported dollars. Infrastructure, staff non-medical excluded. Results: There 210 patients, median age 68.2 years (range 39–90) with 16.6 months. pathology stage distribution were: 3.8% limited small cell (SCLC), 10.0% extensive SCLC, 13.4% I II non-small (NSCLC), 28.5% III NSCLC 44.3% IV NSCLC. estimated total cost for patient cohort A$2.91 million. components staging (10.1%), 41.2% (2.8% surgery, 15.8% radiotherapy 22.6% chemotherapy), hospitalisation (43.7%) (5%). SCLC subgroups A$10 675 A$669–612 789) A$14 799 A$908–31 057), respectively. Conclusion: Hospitalisation treatment, particularly chemotherapy, accounted major management cancer.